Dr. Anil Chandraker is the Medical Director of Kidney and Pancreas Transplantation and the Director of the Transplantation Research Center at the Brigham and Women’s Hospital. He is an Associate Professor Medicine at Harvard Medical School and serves as the Secretary of the American Society of Transplantation.Dr. Chandraker has academic interests in basic, translational and clinical areas of transplantation research. He serves as the overall PI on an NIH sponsored Clinical Trials in Organ Transplantation Consortium examining the development and role of anti HLA antibodies in kidney and heart transplantation. In addition he has clinical/translational research interests in BK nephropathy, anemia and genetics of transplantation.

His basic research interest is focused primarily on T cell costimulatory pathways such as the B7-CD28/CTLA4 and PDL1-PD1 pathways and their role in tolerance and chronic allograft injury. He has mentored eighteen fellows in basic and clinical research and received research funding from the NIH, Juvenile Diabetes Research Foundation and the National Kidney Foundation. He has co-authored over a 120 original scientific articles, review articles and book chapters including contributing chapters to Harrisons, Brenner and Rectors The Kidney, AST Primer on Transplantation and ACP Medicine Textbook.



Chandraker A, Azuma H, Nadeau K, Carpenter CB, Tilney NL, Hancock WW, Sayegh MH. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. Journal of Clinical Investigation 1998; 101: 2309-2318

Yang J, Popoola J, Khandwala S, Vadivel N, Vanguri V, Yuan X, Dada S, Guleria I, Tian C, Ansari MJ, Shin T, Yagita H, Azuma M, Sayegh MH, Chandraker A. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation. 2008 ;1175:660-9

Riella LV, Ueno T, Batal I, De Serres SA, Bassil R, Elyaman W, Yagita H, Medina-Pestana JO, Chandraker A, Najafian N. Blockade of notch ligand delta1 promotes allograft survival by inhibiting alloreactive Th1 cells and cytotoxic T cell generation. J Immunol. 2011 Nov 1;187(9):4629-38.

LeeBT, Kumar V, Williams TA, Abdi R, BernhardyA, Dyer C, Conte S, Genovese G, Ross MD, Friedman DJ, Gaston R, MilfordE, Pollak MR, Chandraker A. The APOL1 Genotype of African American Kidney Transplant Recipients Do Not Impact 5-Year Allograft Survival. Am J Transplant 2012 Jul;12(7):1924-8.

Lee BT, Gabardi S, Grafals M, Hofmann RM, Akalin E, Aljanabi A, Mandelbrot DA, Adey DB, Heher E, Fan PY, Conte S, Dyer-Ward C, Chandraker A. Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol. 2014 Jan 30.


Associate Professor in Medicine, Harvard Medical School

Physician, Brigham and Women’s Hospital

Medical Director of Kidney and Pancreas

Transplantation, Brigham and Women’s Hospital

Director, Transplantation Research Center, Brigham and Women’s Hospital




Glasgow University, Glasgow, Scotland, UK – MB ChB, Medicine, 1987

Royal College of Physicians – FRCP, Medicine, 2005

Medical Residency, Manchester Royal Infirmary, Manchester, UK

Nephrology and Transplant Immunology, Brigham and Women’s Hospital, Harvard Medical School



Awards & Honors

1986 – Certificate of Merit in the subject of General Practice

1996, 1998 – American Society of Transplant Physicians Young Investigators Award

1996-1999 – Juvenile Diabetes Foundation Fellowship Award

1999-2001 – DCI Paul Teschan Award

2000-2002 – National Kidney Foundation Young Investigator Award

2005 – Fellow, Royal College of Physicians (UK)

2006-2009 – National Kidney Foundation Clinical Scientist Award




Phone: 617-525-7412
Fax: 617-732-5254
E-Mail: achandraker@rics.bwh.harvard.edu